ArticleFuture oncology (London, England)2024

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.

Erika P Hamilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.